| 臺大學術典藏 |
2020-04-10T12:16:04Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.;Yu-Yun Shao;Chen H.-M.;Shau W.-Y.;Lin Z.-Z.;Kuo R.N.;Lai C.-L.;Chen K.-H.;Cheng A.-L.;Yang J.C.-H.;Lai M.-S.; Liao B.-C.; YU-YUN SHAO; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
|
Ho W.-C.; Tsai M.-H.; Feng W.-C.; Chow L.-P.; Hsu C.-H.; YU-YUN SHAO; Yeh C.-C.;Hsu C.-H.;Yu-Yun Shao;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Chow L.-P.; Yeh C.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Chan S.-Y.; Shau W.-Y.; YU-YUN SHAO; Yu-Yun Shao;Shau W.-Y.;Chan S.-Y.;Lu L.-C.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
|
Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib
|
Lin T.-H.;Yu-Yun Shao;Chan S.-Y.;Huang C.-Y.;Hsu C.-H.;Cheng A.-L.; Lin T.-H.; YU-YUN SHAO; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yu-Yun Shao;Hsu C.-H.;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Yeh K.-H.; Chen H.-M. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Fu W.-M.; Chen H.-M.; Lee Y.-H.; Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Lin C.-P.; Lin C.-P.;Hsu C.-H.;Fu W.-M.;Chen H.-M.;Lee Y.-H.;Lai M.-S.;Yu-Yun Shao |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; YU-YUN SHAO; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; YU-YUN SHAO; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study
|
Liang Y.-H.;Yu-Yun Shao;Chen H.-M.;Cheng A.-L.;Lai M.-S.;Yeh K.-H.; Liang Y.-H.; YU-YUN SHAO; Chen H.-M.; Cheng A.-L.; Lai M.-S.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; Lu L.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Influence of age on opioid prescription of patients with advanced lung cancer
|
Lee H.-S.;Lin C.-P.;Chen H.-M.;Yu-Yun Shao; Lee H.-S.; Lin C.-P.; Chen H.-M.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Yeh Y.-C.; Chen P.-J.; Lu L.-C.;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Yu-Yun Shao;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; YU-YUN SHAO; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Liang Y.-H.;Wei C.-H.;Hsu W.-H.;Yu-Yun Shao;Lin Y.-C.;Chou P.-C.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Wei C.-H.; Hsu W.-H.; YU-YUN SHAO; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Right or left? Side selection for a totally implantable vascular access device: A randomised observational study
|
Lin W.-Y.;Lin C.-P.;Hsu C.-H.;Lee Y.-H.;Lin Y.-T.;Hsu M.-C.;Yu-Yun Shao; Lin W.-Y.; Lin C.-P.; Hsu C.-H.; Lee Y.-H.; Lin Y.-T.; Hsu M.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan
|
Shen W.-C.;Chen J.-S.;Yu-Yun Shao;Lee K.-D.;Chiou T.-J.;Sung Y.-C.;Rau K.-M.;Yen C.-J.;Liao Y.-M.;Liu T.-C.;Wu M.-F.;Lee M.-Y.;Yu M.-S.;Hwang W.-L.;Lai P.-Y.;Chang C.-S.;Chou W.-C.;Hsieh R.-K.; Shen W.-C.; Chen J.-S.; YU-YUN SHAO; Lee K.-D.; Chiou T.-J.; Sung Y.-C.; Rau K.-M.; Yen C.-J.; Liao Y.-M.; Liu T.-C.; Wu M.-F.; Lee M.-Y.; Yu M.-S.; Hwang W.-L.; Lai P.-Y.; Chang C.-S.; Chou W.-C.; Hsieh R.-K. |
| 臺大學術典藏 |
2020-04-10T12:15:57Z |
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
|
Liu T.-H.;Hsu C.-H.;Yu-Yun Shao; Liu T.-H.; Hsu C.-H.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:15:57Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Yu-Yun Shao;Hsieh M.-S.;Wang H.-Y.;Li Y.-S.;Lin H.;Hsu H.-W.;Huang C.-Y.;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Yu-Yun Shao;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; YU-YUN SHAO; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS
|
Lu Y.-S.; Lin C.-H.; Tsai I.-L.; Kuo C.-H.; YU-YUN SHAO; Chiu H.-H.;Liao H.-W.;Yu-Yun Shao;Lu Y.-S.;Lin C.-H.;Tsai I.-L.;Kuo C.-H.; Chiu H.-H.; Liao H.-W. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of life
|
Chou W.-C.;Chen J.-S.;Hung C.-Y.;Lu C.-H.;Yu-Yun Shao;Chiou T.-J.;Sung Y.-C.;Rau K.-M.;Yen C.-J.;Yeh S.-P.;Liu T.-C.;Wu M.-F.;Lee M.-Y.;Yu M.-S.;Hwang W.-L.;Lai P.-Y.;Chang C.-S.;Hsieh R.-K.; Chou W.-C.; Chen J.-S.; Hung C.-Y.; Lu C.-H.; YU-YUN SHAO; Chiou T.-J.; Sung Y.-C.; Rau K.-M.; Yen C.-J.; Yeh S.-P.; Liu T.-C.; Wu M.-F.; Lee M.-Y.; Yu M.-S.; Hwang W.-L.; Lai P.-Y.; Chang C.-S.; Hsieh R.-K. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study
|
Hwang W.-L.; Liu T.-C.; Yu M.-S.; Sung Y.-C.; Lee K.-D.; Lai P.-Y.; Hsieh R.-K.; Lee M.-Y.; Chiou T.-J.; Yeh S.-P.; Chen J.-S.; Chang C.-S.; Cho S.-F.;Rau K.-M.;Yu-Yun Shao;Yen C.-J.;Wu M.-F.;Chen J.-S.;Chang C.-S.;Yeh S.-P.;Chiou T.-J.;Hsieh R.-K.;Lee M.-Y.;Sung Y.-C.;Lee K.-D.;Lai P.-Y.;Yu M.-S.;Hwang W.-L.;Liu T.-C.; Cho S.-F.; Rau K.-M.; YU-YUN SHAO; Yen C.-J.; Wu M.-F. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.; Yen C.-J.; Chao Y.; Lu L.-C.; Hsu C.; YU-YUN SHAO; Lu L.-C.;Hsu C.;Yu-Yun Shao;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma
|
Yu-Yun Shao;Li Y.-S.;Hsu H.-W.;Lin H.;Wang H.-Y.;Wo R.R.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Guo J.-C.;Lin C.-C.;Lin C.-Y.;Hsieh M.-S.;Kuo H.-Y.;Lien M.-Y.;Yu-Yun Shao;Huang T.-C.;Hsu C.-H.; Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; YU-YUN SHAO; Huang T.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:52Z |
Satisfaction with pain management and impact of pain on quality of life in cancer patients
|
Hwang W.-L.; Chiou T.-J.; Lai P.-Y.; Yen C.-J.; Lin J.; Hsieh R.-K.; Chen J.-S.; Lee K.-D.; Rau K.-M.; YU-YUN SHAO; Sung Y.-C.; Yeh S.-P.; Chang C.-S.; Liu T.-C.; Wu M.-F.; Lee M.-Y.; Yu M.-S. |
| 臺大學術典藏 |
2020-04-09T10:33:05Z |
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
|
Liu, Tsung Hao; Hsu, Chih Hung; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-09T10:30:21Z |
Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS
|
Tsai, I. Lin; Kuo, Ching Hua; Lin, Ching Hung; Lu, Yen Shen; YU-YUN SHAO; Liao, Hsiao Wei; Chiu, Huai Hsuan |
| 臺大學術典藏 |
2019-10-23T13:07:16Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
HUNG-YANG KUO; YU-YUN SHAO; Lin, Chia Chi; Lin, Chen Yuan; Lien, Ming Yu; CHIH-HUNG HSU; Guo, Jhe Cyuan; MIN-SHU HSIEH; Huang, Ta Chen; MIN-SHU HSIEH;CHIH-HUNG HSU;YU-YUN SHAO;HUNG-YANG KUO;Huang, Ta Chen;Guo, Jhe Cyuan;Lien, Ming Yu;Lin, Chen Yuan;Lin, Chia Chi |
| 臺大學術典藏 |
2019-10-23T13:07:16Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
HUNG-YANG KUO; YU-YUN SHAO; Lin, Chia Chi; Lin, Chen Yuan; Lien, Ming Yu; CHIH-HUNG HSU; Guo, Jhe Cyuan; MIN-SHU HSIEH; Huang, Ta Chen; MIN-SHU HSIEH;CHIH-HUNG HSU;YU-YUN SHAO;HUNG-YANG KUO;Huang, Ta Chen;Guo, Jhe Cyuan;Lien, Ming Yu;Lin, Chen Yuan;Lin, Chia Chi |
| 臺大學術典藏 |
2019-09-09T00:55:32Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu, Li Chun;YU-YUN SHAO;Shen, Ying Chun;Hsu, Chiun;YI-PING HUNG;CHIH-HUNG HSU;Liu, Tsung Hao;ANN-LII CHENG;Guo, Jhe Cyuan;Yen, Chia Jui;Chang, Chun Jung;I-LUN SHIH;Chao, Yee; Chao, Yee; I-LUN SHIH; Chang, Chun Jung; Yen, Chia Jui; Guo, Jhe Cyuan; ANN-LII CHENG; Liu, Tsung Hao; CHIH-HUNG HSU; YI-PING HUNG; Hsu, Chiun; Shen, Ying Chun; YU-YUN SHAO; Lu, Li Chun |
| 臺大學術典藏 |
2019-09-09T00:55:32Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu, Li Chun;YU-YUN SHAO;Shen, Ying Chun;Hsu, Chiun;YI-PING HUNG;CHIH-HUNG HSU;Liu, Tsung Hao;ANN-LII CHENG;Guo, Jhe Cyuan;Yen, Chia Jui;Chang, Chun Jung;I-LUN SHIH;Chao, Yee; Chao, Yee; I-LUN SHIH; Chang, Chun Jung; Yen, Chia Jui; Guo, Jhe Cyuan; ANN-LII CHENG; Liu, Tsung Hao; CHIH-HUNG HSU; YI-PING HUNG; Hsu, Chiun; Shen, Ying Chun; YU-YUN SHAO; Lu, Li Chun |
| 臺大學術典藏 |
2019 |
Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma
|
Rita Robin Wo; Ann-Lii Cheng; Chih-Hung Hsu; Han-Yu Wang; Hang Lin; Hung-Wei Hsu; Yong-Shi Li; Yu-Yun Shao; Chih-Hung Hsu;Ann-Lii Cheng;Rita Robin Wo;Han-Yu Wang;Hang Lin;Hung-Wei Hsu;Yong-Shi Li;Yu-Yun Shao |
| 臺大學術典藏 |
2019 |
Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management
|
O'Brien T.; Ahn J.S.; Chye R.; Le B.; Lu H.; Olarte G.; Palladini M.; Salti A.; YU-YUN SHAO; Yaakup H.; Buemio K.C.; Colin C.G.; Hadjiat Y.; O'Brien T.;Ahn J.S.;Chye R.;Le B.;Lu H.;Olarte G.;Palladini M.;Salti A.;Yu-Yun Shao;Yaakup H.;Buemio K.C.;Colin C.G.;Hadjiat Y. |
| 臺大學術典藏 |
2018-09-10T14:53:05Z |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
|
Shao, Y.-Y. and Ho, M.-C. and Cheng, A.-L. and Hsu, C.-H.; Shao, Yu-Yun;Ho, Ming-Chih;Cheng, Ann-Lii;Hsu, Chih-Hung; 邵幼雲;鄭安理;徐志宏;何明志; 邵幼雲;鄭安理;徐志宏;何明志; Shao, Yu-Yun; Shao, Yu-Yun; MING-CHIH HO; CHIH-HUNG HSU; Ho, Ming-Chih; Ho, Ming-Chih; Cheng, Ann-Lii; Yu-Yun Shao; Hsu, Chih-Hung; ANN-LII CHENG; Hsu, Chih-Hung |
| 臺大學術典藏 |
2018-09-10T14:51:53Z |
beta-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma
|
高祥豐;邵幼雲;鄭安理;徐志宏;呂理駿;謝明書;李宜軒; Lu, Li-Chun; MIN-SHU HSIEH; CHIH-HUNG HSU; Shao, Yu-Yun; Lee, Yi-Hsuan; HSIANG-FONG KAO; Yu-Yun Shao; Hsieh, Min-Shu; ANN-LII CHENG; Hsiao, Chi-Huang; Lin, Hsiao-Hui; Kao, Hsiang-Fong; Ma, Yu-Yi; Yen, Feng-Chu; Cheng, Ann-Lii; Hsu, Chih-Hung; Lu, Li-Chun;Shao, Yu-Yun;Lee, Yi-Hsuan;Hsieh, Min-Shu;Hsiao, Chi-Huang;Lin, Hsiao-Hui;Kao, Hsiang-Fong;Ma, Yu-Yi;Yen, Feng-Chu;Cheng, Ann-Lii;Hsu, Chih-Hung; Lu, Li-Chun and Shao, Yu-Yun and Lee, Yi-Hsuan and Hsieh, Min-Shu and Hsiao, Chi-Huang and Lin, Hsiao-Hui and Kao, Hsiang-Fong and Ma, Yu-Yi and Yen, Feng-Chu and Cheng, Ann-Lii and Hsu, Chih-Hung |
| 臺大學術典藏 |
2018-09-10T08:15:22Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao, Y.-Y. and Kuo, K.-T. and Hu, F.-C. and Lu, Y.-S. and Huang, C.-S. and Liau, J.-Y. and Lee, W.-C. and Hsu, C. and Kuo, W.-H. and Chang, K.-J. and Lin, C.-H. and Cheng, A.-L.; CHIUN-SHENG HUANG; Yu-Yun Shao; JAU-YU LIAU; CHING-HUNG LIN; KUAN-TING KUO; ANN-LII CHENG |
| 臺大學術典藏 |
2018 |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H.;Yu-Yun Shao;Lin C.-C.;Kuo S.-H.;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; YU-YUN SHAO; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2017 |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Chen H.-M.; Cheng A.-L.; Lee Y.-H.; Li Y.-S.; Yu-Yun Shao;Lin H.;Li Y.-S.;Lee Y.-H.;Chen H.-M.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Lin H. |
| 臺大學術典藏 |
2017 |
National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients
|
Yu-Yun Shao;Hsiue E.H.-C.;Hsu C.-H.;Yao C.-A.;Chen H.-M.;Lai M.-S.;Cheng A.-L.; YU-YUN SHAO; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2016 |
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study
|
Chen K.-H.; YU-YUN SHAO; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2014 |
Clinical activity of metronomic chemotherapy in liver cancers
|
Hsu C.-H.; Cheng A.-L.; Yu-Yun Shao;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO |
| 臺大學術典藏 |
2013 |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
YU-YUN SHAO; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
